Veracyte | VCYT - Operating Expenses


Veracyte reported $133.73M in Operating Expenses for its fiscal quarter ending in September of 2026.





Operating Expenses Change Date
Agenus USD -199.08M 22.15M Jun/2026
Agilent USD 1.43B 2M Jun/2026
Anika Therapeutics USD 137.28M 3.38M Jun/2026
Arrowhead Research USD 245.35M 30.35M Jun/2026
Bruker USD 790.5M 21.6M Sep/2026
Heron Therapeutics USD 40.55M 1.46M Dec/2025
Illumina USD 525M 374M Sep/2026
Intrexon USD 61.56M 26.1M Jun/2024
Karyopharm Therapeutics USD 61.83M 9.9M Mar/2026
Laboratory Of America USD 3.39B 117.6M Sep/2026
Ligand Pharmaceuticals USD 94.5M 39.4M Sep/2026
Myriad Genetics USD 212.8M 16.2M Dec/2025
Rigel Pharmaceuticals USD 117.61M 35.67M Sep/2025
Roche Holding CHF 18.9B 2.12B Jun/2026
Sangamo BioSciences USD 33.87M 12.89M Jun/2024
Siemens EUR 20.72B 3.12B Sep/2026
Sonic Healthcare AUD 4.23B 2.14B Dec/2024
Thermo Fisher Scientific USD 9.68B 134M Sep/2026
Veracyte USD 133.73M 7.37M Sep/2026
Waters USD 527M 592M Jun/2026